Phio Pharmaceuticals (PHIO) Equity Average (2016 - 2021)
Historic Equity Average for Phio Pharmaceuticals (PHIO) over the last 10 years, with Q3 2021 value amounting to $27.0 million.
- Phio Pharmaceuticals' Equity Average rose 6299.34% to $27.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $27.0 million, marking a year-over-year increase of 6299.34%. This contributed to the annual value of $9.4 million for FY2020, which is 290.28% down from last year.
- According to the latest figures from Q3 2021, Phio Pharmaceuticals' Equity Average is $27.0 million, which was up 6299.34% from $30.1 million recorded in Q2 2021.
- Phio Pharmaceuticals' Equity Average's 5-year high stood at $30.1 million during Q2 2021, with a 5-year trough of $1.2 million in Q1 2018.
- Over the past 5 years, Phio Pharmaceuticals' median Equity Average value was $8.9 million (recorded in 2020), while the average stood at $11.0 million.
- Per our database at Business Quant, Phio Pharmaceuticals' Equity Average plummeted by 8743.59% in 2018 and then surged by 95166.67% in 2019.
- Quarter analysis of 5 years shows Phio Pharmaceuticals' Equity Average stood at $2.6 million in 2017, then skyrocketed by 191.24% to $7.7 million in 2018, then dropped by 12.88% to $6.7 million in 2019, then surged by 113.21% to $14.2 million in 2020, then soared by 89.99% to $27.0 million in 2021.
- Its last three reported values are $27.0 million in Q3 2021, $30.1 million for Q2 2021, and $22.2 million during Q1 2021.